Anthos Therapeutics Inc.

Biopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso

Merger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu

Six years after licensing out abelacimab to Anthos Therapeutics, a venture it co-founded with Blackstone Life Sciences, Novartis has brought the drug back into its cardiovascular pipeline. The Swiss g

Regeneron Pharmaceuticals expects to see downward pressure on the 2mg version of Eylea (aflibercept) continue after 2024, but demand for the VEGF inhibitor has remained high despite the introduction o